Bright Minds Biosciences to Present Latest Advancements at Conferences
News provided byBright Minds Biosciences Inc · 1 min read
NEW YORK, Sept. 04, 2026 /CourierPR/ -- Bright Minds Biosciences, Inc., a leading biotechnology firm developing innovative treatments for neurological and psychiatric disorders, will present at several upcoming conferences. The company focuses on creating highly selective 5-HT2 agonists for drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders.
At the forefront of its research, Bright Minds Biosciences has developed a unique platform of highly selective serotonergic agonists. These compounds exhibit selectivity at different serotonergic receptors, providing a rich portfolio of new chemical entity (NCE) programs within neurology and psychiatry. The company's pipeline includes novel treatments for conditions with high unmet medical needs, including epilepsy, Prader-Willi Syndrome, and depression.
"We are excited to present our latest advancements in drug development at these conferences," said Alex Vasilkevich, Chief Operating Officer of Bright Minds Biosciences. "Our focus on highly selective 5-HT2 agonists holds great promise for transforming the lives of patients with difficult-to-treat neurological and psychiatric conditions."
The upcoming conferences at which Bright Minds Biosciences will present include:
- The Annual Neuroscience Conference in New York City - The International Psychiatry Symposium in Chicago - The Biotech Expo in San Francisco
These events will provide valuable opportunities for the company to share its latest findings and engage with industry experts, potential collaborators, and stakeholders.
Bright Minds Biosciences has been recognized for its innovative approach and commitment to addressing unmet medical needs. The company continues to push the boundaries of what is possible in the field of neurology and psychiatry, aiming to deliver breakthrough therapies that could significantly improve patient outcomes.
By presenting at these conferences, Bright Minds Biosciences is poised to further cement its position as a pioneer in the development of highly selective 5-HT2 agonists and other novel treatments for CNS disorders.